Scientific Results

A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell-derived thyroid carcinoma

Year: 2013

Authors: Plantinga T.S., Costantini I., Heinhuis B., Huijbers A., Semango G., Kusters B., Netea M.G., Hermus A.R.M.M., Smit J.W.A., Dinarello C.A., Joosten L.A.B., Netea-Maier R.T.

Autors Affiliation: Department of Medicine, Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, Nijmegen, 6525 GA, Netherlands; Division of Endocrinology, Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, Nijmegen, 6525 GA, Netherlands; Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, Nijmegen, 6525 GA, Netherlands; Radboud Institute for Oncology, Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, Nijmegen, 6525 GA, Netherlands; Department of Pathology, Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, Nijmegen, 6525 GA, Netherlands; Department of Pathology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ, Maastricht, Netherlands

Abstract: Interleukin (IL)-32 is an intracellular proinflammatory mediatorthat strongly modulates the inflammatory reaction. Recent studieshave suggested the involvement of IL-32 in the pathogenesisof malignancies. We aimed to assess whether a known germ-linepolymorphism in the IL32 promoter modulates IL-32 expression, and whether it influences susceptibility and/or outcome ofepithelial cell-derived thyroid carcinoma (TC). In this study, IL32 genotype was assessed in 139 TC patients and 138 healthycontrols and was correlated with TC susceptibility and clinicaloutcome. Furthermore, IL-32 messenger RNA expression andprotein were assessed in TC tissues and functional consequencesof genetic variants of IL32 were studied in a model of humanprimary immune cells. Results demonstrate substantial IL-32expression in TC tumor tissue. Lipopolysaccharide (LPS) stimulationof primary immune cells revealed 2-fold higher expressionof IL-32? but not IL-32ß, in cells homozygous for the ancient Tallele. Furthermore, production of LPS-induced cytokines wasincreased in cells bearing this T allele. Genetic analysis revealedthat the ancient T allele was overrepresented in TC patients withodds ratio (95% confidence interval) = 1.71 (1.06-2.75). In addition, the cumulative radioactive iodine (RAI) dose received aftertotal thyroidectomy was significantly higher in TC patients bearingthe ancient T allele. In conclusion, individuals bearing geneticvariants of IL32 that lead to an increased IL-32? gene expressionand higher production of proinflammatory cytokines have higherrisk for developing epithelial cell-derived TC. Subsequently, theyrequire higher dosages of RAI to achieve successful tumor remission. These data suggest an important role of IL-32 in the pathogenesisof TC.

Journal/Review: CARCINOGENESIS

Volume: 34 (7)      Pages from: 1529  to: 1535

KeyWords: Interleukin 10; Interleukin 1beta; Interleukin 32; interleukin 32 beta; interleukin 32 gamma; interleukin 6; lipopolysaccharide; messenger RNA; radioactive iodine; tumor necrosis factor alpha; unclassified drug, adult; allele; article; cancer susceptibility; carcinoma cell; cell stimulation; controlled study; correlation analysis; cytokine production; epithelium cell; female; gene dosage; gene expression; genetic analysis; genetic association; genetic variability; genotype; germ line; human; human cell; human tissue; immunocompetent cell; major clinical study; male; priority journal; promoter region; protein expression; single nucleotide polymorphism; thyroid carcinoma; thyroidectomy; tumor regression, Adult; Alleles; Case-Control Studies; Epithelial Cells; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Interleukins; Iodine Radioisotopes; Lipopolysaccharides; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Promoter Regions, Genetic; Risk Factors; Thyroid Neoplasms; Thyroidectomy
DOI: 10.1093/carcin/bgt092

Citations: 28
data from “WEB OF SCIENCE” (of Thomson Reuters) are update at: 2022-01-16
References taken from IsiWeb of Knowledge: (subscribers only)
Connecting to view paper tab on IsiWeb: Click here
Connecting to view citations from IsiWeb: Click here

gdpr-image
This site uses cookies. If you decide to continue browsing we consider that you accept their use. For more information about cookies and how to delete them please read our Info Policy on cookies use.
Read more